LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles
LEON achieved superior accuracy in development of its proprietary reactor, facilitating exceptional inter-device reproducibility of particle size and distribution, and thus seamless process transfer, from development stage to commercial scale. The prerequisites to manufacture the LEON reactor in series are therefore met – a milestone achievement on the road to broad application of the NANOnow product platform for the encapsulation of mRNA in lipid nanoparticles.
Find out more:
PR LEON Reactor development completed
About LEON
leon-nanodrugs GmbH is a Munich-based pharmatech company specializing in the development of devices for the encapsulation of genetic material and other pharmaceutical active substances into nanocarriers, such as lipid nanoparticles (LNPs). LEON builds its innovative solutions based on its proprietary FR-JET technology. Its portfolio of devices, NANOlab® for process development, and NANOme® and NANOus® for GMP aseptic manufacturing, enable faster route to clinical batches and are suitable for both individualised scales and commercial production.
LEON’s platform is aimed at enabling pharma companies, small biotech, research institutes, as well as CDMOs, to take full advantage of the significant progress being made in advanced therapies.
For general information and enquiries please email info@leon-nanodrugs.com